Sisram Medical Ltd (1696.HK) Stock

About Sisram Medical Ltd

Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment, stretch marks, vascular and pigmented lesions, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodeling, injectables, personal care, aesthetic dentistry, hydradermabrasion, blepharoplasty (nonsurgical eyelid lift), liposuction, feminine health, and sexual rehabilitation. It also engages in pharmaceutical research and development activities. The company offers its products under the Alma, LMNT, Copulla, Profhilo, and Aliaxin brands. Sisram Medical Ltd was founded in 1999 and is headquartered in Caesarea, Israel.

Sisram Medical Ltd (1696.HK) stock trades at $2.27 with a market capitalization of $1.06B. The stock is valued at a price-to-earnings (P/E) ratio of 7.08, price-to-book of 0.28, price-to-sales of 2.90. Over the past 52 weeks the stock has ranged between $2.10 and $8.07, and currently trades 71.9% below its 52-week high. It pays a dividend yielding 5.64%.

On profitability, Sisram Medical Ltd generates a return on equity (ROE) of 5.06%, an operating margin of 9.17%, a net profit margin of 5.21%.

Official website: sisram-medical.com